ACOR - Acorda Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
7.43
-0.06 (-0.87%)
As of 3:56PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close7.49
Open7.54
Bid7.45 x 800
Ask7.46 x 800
Day's Range7.40 - 7.86
52 Week Range6.96 - 31.10
Volume598,862
Avg. Volume861,496
Market Cap357.363M
Beta (3Y Monthly)1.68
PE Ratio (TTM)N/A
EPS (TTM)-0.12
Earnings DateJul 31, 2019 - Aug 5, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.56
Trade prices are not sourced from all markets
  • BioMarin Gets $15M From Pfizer on Talzenna's European Nod
    Zacks5 hours ago

    BioMarin Gets $15M From Pfizer on Talzenna's European Nod

    BioMarin (BMRN) gains a $15-million milestone from Pfizer on the approval of its breast cancer drug in Europe.

  • Vertex's (VRTX) Symdeko Gets FDA Nod for Use in Children
    Zacks6 hours ago

    Vertex's (VRTX) Symdeko Gets FDA Nod for Use in Children

    Vertex's (VRTX) Symdeko gets FDA approval to treat underlying cause of cystic fibrosis in children aged 6-11 years with certain mutations in the CFTR gene.

  • Alexion's sBLA for Ultomiris Gets Priority Review From FDA
    Zacks3 days ago

    Alexion's sBLA for Ultomiris Gets Priority Review From FDA

    The FDA accepts Alexion's (ALXN) sBLA for Ultomiris under priority review for treating atypical hemolytic uremic syndrome to inhibit complement-mediated thrombotic microangiopathy. Shares increase.

  • Here’s What Hedge Funds Think About Acorda Therapeutics Inc (ACOR)
    Insider Monkey4 days ago

    Here’s What Hedge Funds Think About Acorda Therapeutics Inc (ACOR)

    "The global economic environment is very favorable for investors. Economies are generally strong, but not too strong. Employment levels are among the strongest for many decades. Interest rates are paused at very low levels, and the risk of significant increases in the medium term seems low. Financing for transactions is freely available to good borrowers, […]

  • Akari (AKTX) Eye Candidate Proves Safety in Early-Stage Study
    Zacks4 days ago

    Akari (AKTX) Eye Candidate Proves Safety in Early-Stage Study

    Akari (AKTX) presents favorable safety data from part A of an early-stage study on nomacopan for treating moderate to severe atopic keratoconjunctivitis. Shares appreciate.

  • Alexion's (ALXN) Ultomiris Gets Approval in Japan for PNH
    Zacks5 days ago

    Alexion's (ALXN) Ultomiris Gets Approval in Japan for PNH

    Alexion (ALXN) receives approval in Japan for its long-acting C5 complement inhibitor, Ultomiris, for the PHN indication.

  • Intrexon Up on Striking 100M Cannabinoid Deal With Surterra
    Zacks5 days ago

    Intrexon Up on Striking 100M Cannabinoid Deal With Surterra

    Intrexon (XON) inks a $100-million worth exclusive licensing deal with Surterra to produce cannabinoid in a reliable and cost-effective fashion, using its own yeast fermentation process. Shares climb.

  • Autolus Therapeutics (AUTL) in Focus: Stock Moves 8.5% Higher
    Zacks5 days ago

    Autolus Therapeutics (AUTL) in Focus: Stock Moves 8.5% Higher

    Autolus Therapeutics (AUTL) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

  • Arena Initiates Dosing in Pivotal Colitis Study on Etrasimod
    Zacks6 days ago

    Arena Initiates Dosing in Pivotal Colitis Study on Etrasimod

    Arena (ARNA) doses first patient in one of the two pivotal late-stage studies evaluating its pipeline candidate, etrasimod in ulcerative colitis indication.

  • Protalix (PLX) Completes Enrollment in Fabry Disease Study
    Zacks6 days ago

    Protalix (PLX) Completes Enrollment in Fabry Disease Study

    Protalix (PLX) closes enrollment in the late-stage study on PRX-102, currently being developed for the treatment of patients with Fabry disease.

  • Five Prime Therapeutics (FPRX) Looks Good: Stock Adds 9.2% in Session
    Zacks6 days ago

    Five Prime Therapeutics (FPRX) Looks Good: Stock Adds 9.2% in Session

    Five Prime Therapeutics (FPRX) shares rose more than 9% in the last trading session, amid huge volumes.

  • Markit6 days ago

    See what the IHS Markit Score report has to say about Acorda Therapeutics Inc.

    Acorda Therapeutics Inc NASDAQ/NGS:ACORView full report here! Summary * Bearish sentiment is high * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is high for ACOR with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting ACOR. However, the last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold ACOR had net inflows of $2.37 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Alexion's (ALXN) PNH Drug Ultomiris Shows Long-Term Efficacy
    Zacks7 days ago

    Alexion's (ALXN) PNH Drug Ultomiris Shows Long-Term Efficacy

    Alexion (ALXN) reports positive data on Ultomiris in adult patients with paroxysmal nocturnal hemoglobinuria.

  • Dr. Reddy's Inks Deal to Sell Neurology Branded Products
    Zacks10 days ago

    Dr. Reddy's Inks Deal to Sell Neurology Branded Products

    Dr. Reddy's (RDY) announced that it has entered a definitive asset purchase agreement with Upsher-Smith Laboratories, LLC to sell its neurology branded products.

  • Catalyst Pharma Files Lawsuit Against FDA Approval of Ruzurgi
    Zacks11 days ago

    Catalyst Pharma Files Lawsuit Against FDA Approval of Ruzurgi

    Catalyst Pharma (CPRX) files lawsuit against FDA's approval of Jacobus Pharmaceutical Co's drug, Ruzurgi, for the treatment of LEMS in pediatric patients.

  • NuCana's Biliary Tract Cancer Candidate Gets Orphan Drug Tag
    Zacks11 days ago

    NuCana's Biliary Tract Cancer Candidate Gets Orphan Drug Tag

    The FDA confers an orphan drug designation on NuCana's (NCNA) pipeline candidate, Acelarin, for treating patients with biliary tract cancer

  • Acorda Therapeutics Enters Oversold Territory
    Zacks11 days ago

    Acorda Therapeutics Enters Oversold Territory

    Acorda Therapeutics, Inc. (ACOR) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

  • Denali's Hunter Syndrome Candidate Gets Orphan Drug Status
    Zacks12 days ago

    Denali's Hunter Syndrome Candidate Gets Orphan Drug Status

    The FDA assigns an orphan drug designation and a rare pediatric disease designation to Denali's (DNLI) pipeline candidate, DNL310, for treating patients with Hunter Syndrome. Shares inch up.

  • Athenex Rallies on Positive Early Data on Psoriasis Candidate
    Zacks14 days ago

    Athenex Rallies on Positive Early Data on Psoriasis Candidate

    Athenex (ATNX) shares rise on encouraging preliminary data from an early-stage study on KX2-391, currently under development for treating patients with psoriasis.

  • BioMarin's Vimizim Wins Nod in China for Rare Genetic Malady
    Zacks18 days ago

    BioMarin's Vimizim Wins Nod in China for Rare Genetic Malady

    BioMarin's (BMRN) Vimizim gains an NMPA nod in China for addressing patients suffering Morquio A syndrome, an ultra-rare genetic condition.

  • Reata's (RETA) Kidney Candidate Gets Orphan Drug Status
    Zacks18 days ago

    Reata's (RETA) Kidney Candidate Gets Orphan Drug Status

    The FDA bestows an orphan drug designation on Reata Pharmaceuticals' (RETA) candidate, bardoxolone, for treating patients with autosomal dominant polycystic kidney disease.

  • Myriad Genetics Announces Study Results Of myRisk Cancer Test
    Zacks19 days ago

    Myriad Genetics Announces Study Results Of myRisk Cancer Test

    The results of the studies will provide a major breakthrough for Myriad Genetics (MYGN) in the field of breast cancer diagnosis and treatment.

  • Seattle Genetics, Astellas' Cancer Candidate Attains 44% ORR
    Zacks20 days ago

    Seattle Genetics, Astellas' Cancer Candidate Attains 44% ORR

    Seattle Genetics (SGEN) and Astellas post favorable data from the first cohort of a phase II study on enfortumab vedotin for treating advanced/metastatic urothelial cancer. Shares up as the candidate achieves 44% ORR.